Preoperative Taxane-Based Chemotherapy and Celecoxib for Carcinoma of the Esophagus and Gastroesophageal Junction: Results of a Phase 2 Trial Nasser.

Slides:

Advertisements

Similar presentations

Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell.

Advertisements

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 Marie Florescu,

Mature Results from a Phase II Trial of Postoperative Concurrent Chemoradiotherapy for Poor Prognosis Cancer of the Esophagus and Gastroesophageal Junction

Phase II Study of Preoperative Pemetrexed, Carboplatin, and Radiation Followed by Surgery for Locally Advanced Esophageal Cancer and Gastroesophageal.

Irinotecan, Carboplatin, and Imatinib in Untreated Extensive-Stage Small-Cell Lung Cancer: A Phase II Trial of the Minnie Pearl Cancer Research Network

Thoracoscopic lobectomy is associated with lower morbidity than open lobectomy: A propensity-matched analysis from the STS database Subroto Paul, MD,

Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Phase II Clinical Trial of First or Second-Line Treatment with Bortezomib in Patients with Malignant Pleural Mesothelioma Dean A. Fennell, PhD, FRCP,

Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus Yang Zhao, MD, ZhiJun Dai,

A Propensity-Matched Analysis of Wedge Resection and Stereotactic Body Radiotherapy for Early Stage Lung Cancer Jeffrey L. Port, MD, Bhupesh Parashar,

Characteristics and outcomes of secondary nodules identified on initial computed tomography scan for patients undergoing resection for primary non–small.

Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer Wolf Köster, MD, Andrea Heider, MD, Norbert.

Irinotecan, Carboplatin, and Imatinib in Untreated Extensive-Stage Small-Cell Lung Cancer: A Phase II Trial of the Minnie Pearl Cancer Research Network

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901 Stephen L. Graziano,

Long-Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non–Small Cell Lung Cancer: A Phase II Clinical Trial

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 Marie Florescu,

Gemcitabine and Irinotecan for Patients with Untreated Extensive Stage Small Cell Lung Cancer: SWOG 0119 Wallace Akerley, MD, Jason McCoy, MS, Paul J.

Prevalence, outcomes, and a risk–benefit analysis of diaphragmatic hernia admissions: An examination of the National Inpatient Sample database Subroto.

Lobectomy in Octogenarians With Non-Small Cell Lung Cancer: Ramifications of Increasing Life Expectancy and the Benefits of Minimally Invasive Surgery

Clinical T2-T3N0M0 Esophageal Cancer: The Risk of Node Positive Disease Brendon M. Stiles, MD, Farooq Mirza, MD, Anthony Coppolino, MD, Jeffrey L. Port,

Brendon M. Stiles, MD, Farooq Mirza, MD, Jeffrey L. Port, MD, Paul C

Mohamed K. Kamel, MD, Mohamed Rahouma, MD, Benjamin Lee, MD, Sebron W

Phase II Trial of Paclitaxel and Cisplatin in Patients with Extensive Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Trial 9430 Thomas E.

Pulmonary Resection for Metastatic Gastric Cancer

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Standard Outcome Measures for Thymic Malignancies

Meta-Analysis of First-Line Therapies in Advanced Non–Small-Cell Lung Cancer Harboring EGFR-Activating Mutations Benjamin Haaland, PhD, Pui San Tan,

Second-line or Subsequent Systemic Therapy for Recurrent or Progressive Non-Small Cell Lung Cancer: A Systematic Review and Practice Guideline J Noble,

Propensity score–matched analysis of adjuvant chemotherapy for stage I non–small cell lung cancer Yasuhiro Tsutani, MD, PhD, Yoshihiro Miyata, MD, PhD,

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non–Small Cell Lung Cancer: NCCTG N0028 (Alliance)

The Applicability of the Proposed IASLC Staging Revisions to Small Cell Lung Cancer (SCLC) with Comparison to the Current UICC 6th TNM Edition Sai-Hong.

Phase II Trial of Irinotecan, Carboplatin, and Bevacizumab in the Treatment of Patients with Extensive-Stage Small-Cell Lung Cancer David R. Spigel,

Clinical Outcomes and Prognosis of Recurrent Thymoma Management

Predictors of recurrence and disease-free survival in patients with completely resected esophageal carcinoma Paul C. Lee, MD, Farooq M. Mirza, MD, Jeffrey.

Chemotherapy in Patients ≥80 with Advanced Non-small Cell Lung Cancer: Combined Results from SWOG 0027 and LUN 6 Paul J. Hesketh, MD, Rogerio C. Lilenbaum,

Postinduction positron emission tomography assessment of N2 nodes is not associated with ypN2 disease or overall survival in stage IIIA non–small cell.

Re-evaluation of the Role of Postoperative Radiotherapy and the Impact of Radiation Dose for Non–Small-Cell Lung Cancer Using the National Cancer Database

Brendon M. Stiles, MD, Mohamed K. Kamel, MD, Sebron W

Predictors of Long-Term Survival After Resection of Esophageal Carcinoma With Nonregional Nodal Metastases Paul C. Lee, MD, Jeffrey L. Port, MD, Subroto.

PUB010 Intraoperative Blood Loss is an Independent Predictor of Poor Disease Free Survival for Patients Undergoing VATS Lobectomy for Lung Cancer M.

Phase II Randomized Trial of Erlotinib or Vinorelbine in Chemonaive, Advanced, Non- small Cell Lung Cancer Patients Aged 70 Years or Older Yuh-Min Chen,

Combination Chemotherapy with Irinotecan and Cisplatin for Large-Cell Neuroendocrine Carcinoma of the Lung: A Multicenter Phase II Study Seiji Niho,

P. Leland Oviatt, MD, David R

Phase II Study of Bendamustine in Relapsed Chemotherapy Sensitive or Resistant Small-Cell Lung Cancer Philip E. Lammers, MD, Yu Shyr, PhD, Chung-I Li,

A Double-Blind Randomized Discontinuation Phase-II Study of Sorafenib (BAY 43– 9006) in Previously Treated Non–Small-Cell Lung Cancer Patients: Eastern.

A Phase 2 Randomized Trial of Paclitaxel and Carboplatin with or without Panitumumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

Relationship between Response and Survival in More Than 50,000 Patients with Advanced Non-small Cell Lung Cancer Treated with Systemic Chemotherapy in.

DHA-Paclitaxel (Taxoprexin) as First-Line Treatment in Patients with Stage IIIB or IV Non-small Cell Lung Cancer: Report of a Phase II Open-Label Multicenter.

Phase 2 Study of Sorafenib in Malignant Mesothelioma Previously Treated with Platinum-Containing Chemotherapy Sophie Papa, MRCP, PhD, Sanjay Popat, FRCP,

A Phase II Study of Concurrent Chemoradiation with Weekly Docetaxel, Carboplatin, and Radiation Therapy Followed by Consolidation Chemotherapy with Docetaxel.

Phase II Study of Perioperative Chemotherapy with Cisplatin and Pemetrexed in Non– Small-Cell Lung Cancer Grace K. Dy, MD, Paul N. Bogner, MD, Wei Tan,

Immune-Modulating Vaccines in Non-small Cell Lung Cancer

Pulmonary Resection for Metastases from Colorectal Cancer

Prevalence and Outcomes of Anatomic Lung Resection for Hemoptysis: An Analysis of the Nationwide Inpatient Sample Database Subroto Paul, MD, Weston Andrews,

The Annals of Thoracic Surgery

Extent of lymphadenectomy is associated with oncological efficacy of sublobar resection for lung cancer ≤2 cm Brendon M. Stiles, MD, Jialin Mao, MD,

Prospective Assessment of Continuation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition.

Tivantinib in Combination with Erlotinib versus Erlotinib Alone for EGFR-Mutant NSCLC: An Exploratory Analysis of the Phase 3 MARQUEE Study Giorgio V.

PUB006 Impact of the New WHO Classification of Thymic Tumors: Cross-Validation of the Prognostic Value in a Single Institution Cohort Mohamed Kamel,

Predictors of Pleural Implants in Patients With Thymic Tumors

A Randomized, Phase II Trial of Two Dose Levels of Temsirolimus (CCI-779) in Patients with Extensive-Stage Small-Cell Lung Cancer Who Have Responding.

A Randomized Phase II Trial Assessing in Advanced Non-small Cell Lung Cancer Patients with Stable Disease after Two Courses of Cisplatin-Gemcitabine an.

Thoracoscopic lobectomy is associated with lower morbidity than open lobectomy: A propensity-matched analysis from the STS database Subroto Paul, MD,

Video-Assisted Thoracoscopic Surgery Is a Safe and Effective Alternative to Thoracotomy for Anatomical Segmentectomy in Patients With Clinical Stage I.

Preoperative chemotherapy for esophageal cancer with paclitaxel and carboplatin: results of a phase II trial R.S Keresztes, MD, J.L Port, MD, M.W Pasmantier,

Presentation transcript:

Preoperative Taxane-Based Chemotherapy and Celecoxib for Carcinoma of the Esophagus and Gastroesophageal Junction: Results of a Phase 2 Trial Nasser K. Altorki, MD, Paul Christos, DrPH, Jeff L. Port, MD, Paul C. Lee, MD, Farooq Mirza, MD, Cathy Spinelli, RN, Roger Keresztes, MD, Debra Beneck, MD, Subroto Paul, MD, Brendon M. Stiles, MD, Yuwei Zhang, MD, David S. Schrump, MD, MBA Journal of Thoracic Oncology Volume 6, Issue 6, Pages 1121-1127 (June 2011) DOI: 10.1097/JTO.0b013e31821529a9 Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Overall survival (OS) for the entire cohort. N = 39 patients, 25 deaths. Median OS time = 31.1 months (95% confidence interval [CI] = 18.5–59.4). Four-year OS = 40.9% (95% CI = 25.5–55.7%). Journal of Thoracic Oncology 2011 6, 1121-1127DOI: (10.1097/JTO.0b013e31821529a9) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Disease-free survival (DFS) for the entire cohort. N = 39 patients, 28 recurrences or deaths. Median DFS = 24.0 months (95% confidence interval [CI] = 13.0–37.7 months). Four-year DFS = 30.3% (95% CI = 16.7–45.0%). Journal of Thoracic Oncology 2011 6, 1121-1127DOI: (10.1097/JTO.0b013e31821529a9) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Overall survival (OS) comparison between expressors and nonexpressors of cyclooxygenase (COX)-2. No expression: N = 14 patients, 11 deaths. Median OS time = 26.2 months (95% confidence interval [CI] = 12.1–43.7). Four-year OS = 21.4% (95% CI = 5.2–44.8%). Expression: N = 21 patients, 12 deaths. Median OS time = 38.1 months (95% CI = 17.0, not estimated). Four-year OS = 47.6% (95% CI = 25.7–66.7%). Journal of Thoracic Oncology 2011 6, 1121-1127DOI: (10.1097/JTO.0b013e31821529a9) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions